Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Expenses (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Operating Expenses for 16 consecutive years, with $97.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 53.74% to $97.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $367.3 million through Dec 2025, up 53.39% year-over-year, with the annual reading at $367.3 million for FY2025, 53.39% up from the prior year.
  • Operating Expenses hit $97.6 million in Q4 2025 for Vanda Pharmaceuticals, up from $87.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $97.6 million in Q4 2025 to a low of $44.8 million in Q3 2023.
  • Historically, Operating Expenses has averaged $64.4 million across 5 years, with a median of $59.9 million in 2021.
  • Biggest five-year swings in Operating Expenses: decreased 27.03% in 2023 and later soared 60.62% in 2025.
  • Year by year, Operating Expenses stood at $59.4 million in 2021, then fell by 2.58% to $57.9 million in 2022, then dropped by 9.49% to $52.4 million in 2023, then increased by 21.2% to $63.5 million in 2024, then skyrocketed by 53.74% to $97.6 million in 2025.
  • Business Quant data shows Operating Expenses for VNDA at $97.6 million in Q4 2025, $87.5 million in Q3 2025, and $91.1 million in Q2 2025.